ABOUT US

NEWS

INVESTOR RELATIONS

简 繁 EN
Essex-Bio Group
简 繁 EN
简 繁 EN
COMPANY NEWS
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023.08.16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023.07.26
EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”
2023.06.30
Time
Last 7 days Last 30 days The last six months
Date
Title
2023-08-16
Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance
2023-08-16
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-07-26
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-06-30
EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”
2023-04-14
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
2023-04-11
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China
2023-03-08
Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance
2023-03-08
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
< 1 2 3 4 5 6 7 ... 8 
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy
粤公网安备 44049102496184号粤ICP备09032349号-1 深圳网站建设 深圳联雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT